Theseus Pharmaceuticals, which aimed to overcome the resistance that cancers develop to drugs, is laying off most of its staff and exploring options that could lead to deals that eke out some value ...
It’s been a wild November for Theseus Pharmaceuticals. Just a couple of weeks ago, the biotech laid off almost three-quarters of its staff. Days later, the company received offers from two sets of ...
On February 18, 2024, Ian Laffey posted on X that he and two others he’d just met built a cheap drone at a hackathon that calculated its coordinates simply by using its camera and Google Maps. He and ...
Concentra Biosciences’ spread-betting on biotech acquisitions has finally reeled in another win in 2023, with Theseus Pharmaceuticals taking up the offer of the buyout. Over the last few weeks, ...
-- Theseus Stockholders to Receive $4.05 Per Share in Cash Plus Contingent Value Right -- The tender offer and related withdrawal rights expired at 6:00 p.m. Eastern Time on February 13, 2024 (the ...
-- Company prioritizing THE-349, a potentially best-in-class fourth-generation EGFR inhibitor for EGFR mutant non-small cell lung cancer; IND on track for submission in Q4 2023 -- -- Theseus announces ...
As a snot-nosed child, Greek mythological tales always held a certain kind of irresistible fascination for me. Whether it was the adventures of Jason and the Argonauts, or the endlessly impressive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results